Trial Profile
A pilot study to evaluate feasibility and safety of early switch to everolimus from cyclosporine in de novo renal transplant.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2014
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2011 Planned end date Jul 2007 as reported by ClinicalTrials.gov.
- 07 Jul 2007 New trial record.